Correlation of low levels of nitrite and high levels of fetal hemoglobin in patients with sickle cell disease at baseline.
Autor: | Elias DB; Universidade Federal do Ceará - UFC, Fortaleza, CE, Brazil]., Rocha LB, Cavalcante MB, Pedrosa AM, Justino IC, Gonçalves RP |
---|---|
Jazyk: | angličtina |
Zdroj: | Revista brasileira de hematologia e hemoterapia [Rev Bras Hematol Hemoter] 2012; Vol. 34 (4), pp. 265-9. |
DOI: | 10.5581/1516-8484.20120069 |
Abstrakt: | Background: Sickle cell disease is a hemoglobinopathy characterized by hemolytic anemia, increased susceptibility to infections and recurrent vaso-occlusive crises that reduces the quality of life of sufferers. Objective: To evaluate the correlation of the levels of lactate dehydrogenase, malonaldehyde and nitrite to fetal hemoglobin in patients with sickle cell disease not under treatment with hydroxyurea in outpatients at a university hospital in Fortaleza, Ceará, Brazil. Methods: Forty-four patients diagnosed with sickle cell disease were enrolled at baseline. Diagnosis was confirmed by evaluating the beta globin gene using polymerase chain reaction-restriction fragment length polymorphism. The concentration of fetal hemoglobin was obtained by high-performance liquid chromatography. Serum levels of nitrite, malonaldehyde and lactate dehydrogenase were measured by biochemical methods. Results: Significantly higher levels of lactate dehydrogenase, nitrite and malonaldehyde were observed in patients with sickle cell disease compared to a control group. The study of the correlation between fetal hemoglobin levels and these variables showed a negative correlation with nitrite levels. No correlation was found between fetal hemoglobin and malonaldehyde or lactate dehydrogenase. When the study population was stratified according to fetal hemoglobin levels, a decrease in the levels of nitrite was observed with higher levels of fetal hemoglobin (p-value = 0.0415). Conclusion: The results show that, similar to fetal hemoglobin levels, the concentration of nitrite can predict the clinical course of the disease, but should not be used alone as a modulator of prognosis in patients with sickle cell disease. |
Databáze: | MEDLINE |
Externí odkaz: |